Doxorubicin in Disseminated

Cortes, Engracio P.

doi:10.1001/jama.1972.03200230020005

Cited by 118 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase II studies of single agents and combinations of drugs have documented the efficacy of methotrexate (MTX), doxorubicin (DXR) and cisplatin (CDDP) in advanced osteosarcoma ( 4 – 6 ), leading to randomized studies confirming the efficacy of adjuvant chemotherapy ( 7 , 8 ). This three-drug combination represents the standard care for osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

et al. 2014

View full text Add to dashboard Cite

The present study investigated the safety and efficacy of neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcoma in adult and older patients. A total of 18 consecutive patients with bone sarcoma (American Joint Committee on Cancer stage II in 14 patients and stage IV in four) treated with neoadjuvant and adjuvant chemotherapy at Nagoya Musculoskeletal Oncology Group hospitals in Japan between 2004 and 2011 were reviewed. The treatment efficacy and side-effects were evaluated. The responses to neoadjuvant chemotherapy were stable disease in 11 patients and progressive disease in three. Among the 12 evaluable patients, there were five with ≥90% tumor necrosis. The estimated overall survival (OS) rate at five years for the patients without metastasis prior to treatment was 56%. Major grade 3 or 4 side-effects included leukopenia in 14 cases, anemia in seven, thrombocytopenia in three, nausea in two and febrile neutropenia in two. One patient discontinued chemotherapy due to a temporarily depressed level of consciousness with arrhythmia (grade 2). The estimated five-year OS rate in this study was acceptable in patients without metastasis prior to treatment. A better coordinated prospective study of this combination regimen for older patients with bone sarcoma will be required to clarify its efficacy and tolerability.

show abstract

Section: Introductionmentioning

confidence: 99%

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Responses were rare and when they occurred were seldom complete or durable. In 1972 Jaffe et a1 [16] and Cortes et a1 [17] reported on the efficacy of high-dose methotrexate and of Adriamycin in metastatic osteogenic sarcoma. Rosen et a1 [ 181 in 1974 gave the results of the combination of high dose methotrexate and Adriamycin for metastatic disease.…”

Section: Ciolio D'angio MD (Pediatric Radiotherapist)mentioning

confidence: 99%

Osteogenic sarcoma

Raney

D’Angio

Mitchell

et al. 1985

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Christopher Mitchell, MB, MRCPThe purpose of today's Tumor Board discussion is to consider current options for treatment of osteogenic sarcoma as illustrated by a patient recently seen at the Children's Hospital of Philadelphia (CHP), and to discuss the optimal management of this condition today.A 13-year-old white girl first came to medical attention when she complained of left thigh pain and swelling which had begun 4 weeks earlier. The only previous medical problem of note was a 1-year period of observation for scoliosis. Examination at an outside hospital was normal except for a swollen and tender left thigh. A roentgenogram of the left femur showed bony destruction located in the diaphysis. A chest x-ray revealed a single, right-sided pulmonary nodule at the level of the ninth rib. This finding was confirmed by a computerized tomographic (CT) scan; no other nodules were seen. A radionuclide bone scan showed uptake in the left femur. Biopsy revealed the presence of osteogenic sarcoma, and she was then referred to CHP for further treatment.Pre-operative chemotherapy was administered, consisting of four courses of high-dose methotrexate, followed by two courses of bleomycin, cyclophosphamide and actinomycin D. During this period, serial chest xrays showed no progression of disease and she experienced relief of pain in her left thigh. She subsequently underwent a limb-salvage procedure and then continued the adjuvant chemotherapy. Subsequent CT scans showed development of further pulmonary metastases. Two and one-half months after resection of the primary tumor, she underwent bilateraI thoracotomies. A total of 31 nodules were removed from the parenchyma of both lungs. She then received further chemotherapy, but her chest x-ray films subsequently showed progressive pulmonary disease. She received two further courses of high-dose methotrexate without response. Chemotherapy was then discontinued. At present she is receiving only supportive care.Dr. Ellis, would you please outline the surgical considerations in this condition and the orthopedic treatment of this patient? Ronald D. Ellis, MD (Pediatric Orthopedic Surgeon)

show abstract

“…Both high-dose methotrexate [14,15] and adriamycin [13] have demonstrated definite antitumor activity in metastatic osteosarcoma. Consistent and significant tumoricidal effects have been produced on the primary lesion when high-dose methotrexate is used preoperatively [ 16-181. drugs, the time intervals between courses of the same drug or of different drugs, the duration of therapy and/or the actual doses given.…”

Section: Discuss1 Onmentioning

confidence: 99%

Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study

Herson

Sutow

Elder

et al. 1980

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

This report updates experience with the CONPADRI-I, COMPADRI-II, and COMPADRI-III adjuvant chemotherapy programs for the treatment of nonmetastatic osteosarcoma. A total of 200 patients received one of the three regimens. The analysis of response to treatment is based on disease-free survival time (DFS time). The effect of treatment, age, sex, site of disease involvement, and race on DFS time were investigated. Cox's life-table regression analysis found only sex to have a significant effect on DFS time with males having 1.8 times the risk of recurrence or death per unit time as female patients (P = 0.004). An analysis of the 81 patients still alive and disease-free 18 months after the start of treatment shows significantly longer DFS time for CONPADRI-I than COMPADRI-II patients (P = 0.01). This trend is true for both male (P = 0.12) and female (P = 0.08) patients.

show abstract

Doxorubicin in Disseminated

Cited by 118 publications

References 8 publications

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients

Osteogenic sarcoma

Adjuvant chemotherapy in nonmetastatic osteosarcoma: A southwest oncology group study

Contact Info

Product

Resources

About